Q1 YTD/FY2026 Financial Results

The presentation was conducted in both English and Japanese with simultaneous interpretation.
Please note that the accuracy of the interpretation cannot be fully guaranteed.

from the beginning

Q1 YTD/FY2026 Financial Results

Cautionary Statement Regarding Forward-Looking Information

Q1 YTD/FY2026 Overview

I Q1 YTD/FY2026 Consolidated Financial Results

• Q1 YTD/FY2026 Financial Results

• Q1 YTD/FY2026 Financial Results: Main Brands

• Q1 YTD/FY2026 Financial Results: Cost Items

II Pipeline Progress

• Strategic Brands: Progress of Lifecycle Management

• Pipeline Progress

• Progress in ASP546C

• Progress in setidegrasib

• Expanding Primary Focus: From “Targeted Protein Degradation” to a Broader “Induced Proximity” Platform

• Key Takeaways

Appendix

• Strategic Brands: Potential Peak Sales (as of Jul 2026)

• Capital Allocation Policy

• Q1 YTD/FY2026 Actual: FX Rate

• FY2026 Forecast: FX Rate & FX Sensitivity

• Balance Sheet & Cash Flow Highlights

• Balance of Bonds and Borrowings Highlights

• Main Intangible Assets (as of Jun 30, 2026)

• Disciplined Cost Optimization

• Our Pipeline

• Progress in Overall Pipeline

• enfortumab vedotin (EV) (1/4): Nectin-4 Targeted ADC Number of Eligible Patients

• enfortumab vedotin (EV) (2/4): Clinical Studies

• enfortumab vedotin (EV) (3/4): Study Data by Disease Stage

• enfortumab vedotin (EV) (4/4): Development for Muscle-Invasive Bladder Cancer (MIBC)

• zolbetuximab: anti-Claudin 18.2 Monoclonal Antibody

• fezolinetant: NK3 Receptor Antagonist

• gilteritinib: FLT3 Inhibitor

• setidegrasib: KRAS G12D Degrader

• ASP2138: T-cell Engager Targeting Claudin 18.2 and CD3

• Portfolio of Claudin 18.2-Targeted Therapies

• ASP7317: Retinal Pigment Epithelial Cell

• AT845: AAV8 Based Gene Therapy Expressing hGAA Gene

• VIR-5500: Dual-masked CD3 T-cell Engager Targeting PSMA

Q&A

• Q&A1

• Q&A2

• Q&A3

• Q&A4

• Q&A5

• Q&A6

• Q&A7

• Q&A8